

# Pharmacokinetic effects of a single-dose nutritional ketone ester supplement on brain ketone and glucose metabolism in alcohol use disorder – a pilot study

- 1 Xinyi Li<sup>1</sup>, Anthony J. Young<sup>2</sup>, Lais S. Pereira-Rufino<sup>1</sup>, Zhenhao Shi<sup>1</sup>, Juliana Byanyima<sup>1</sup>,
- 2 Sianneh Vesslee<sup>1</sup>, Rishika Reddy<sup>1</sup>, Timothy Pond<sup>1</sup>, Mark Elliott<sup>2</sup>, Ravinder Reddy<sup>2</sup>, Robert K.
- 3 Doot<sup>2</sup>, Jan-Willem van der Veen<sup>3</sup>, Henry R. Kranzler<sup>1</sup>, Ravi Prakash Reddy Nanga<sup>2</sup>, Jacob G.
- 4 **Dubroff<sup>2</sup>**, Corinde E. Wiers<sup>1</sup>
- <sup>1</sup>Center for Studies of Addiction, University of Pennsylvania Perelman School of Medicine,
   Department of Psychiatry, Philadelphia, PA
- 7 <sup>2</sup>University of Pennsylvania Perelman School of Medicine, Department of Radiology, Philadelphia,
- 8 PA
- <sup>9</sup> <sup>3</sup>National Institute on Mental Health, National Institutes of Health, 10 Center Drive, Bethesda, MD

#### 10 **\* Correspondence:**

- 11 Corinde E. Wiers, Ph.D.
- 12 corinde.wiers@pennmedicine.upenn.edu
- 13
- 14 **Keywords:** beta-hydroxybutyrate, brain energetics, ketogenic diet, krebs cycle, metabolism,
- 15 nutritional supplement

16

#### 17 Abstract

18 Introduction: Acute alcohol intake decreases brain glucose metabolism and increases brain uptake of

- 19 acetate, a metabolite of alcohol. Individuals with alcohol use disorder (AUD) show elevated brain
- 20 acetate metabolism at the expense of glucose, a shift in energy utilization that persists beyond acute
- 21 intoxication. We recently reported that nutritional ketosis and administration of ketone bodies as an
- 22 alternative energy source to glucose reduce alcohol withdrawal severity and alcohol craving in AUD. 23
- However, the regional effects of nutritional ketosis on brain ketone (beta-hydroxybutyrate [BHB]) and
- 24 glucose metabolism have not been studied in AUD.
- 25 Methods: Five participants with AUD underwent two magnetic resonance imaging (MRI) sessions and
- 26 4 participants with AUD underwent two positron emission tomography (PET) sessions with <sup>18</sup>F-
- 27 fluorodeoxyglucose. All participants completed one session without KE intervention and one session during which they consumed 395 mg/kg (R)-3-hydroxybutyl (R)-3-hydroxybutyrate Ketone Ester (KE) 28
- 29 intervention (TdeltaS Global Inc.) before the scan. The order of the sessions was randomized. For the
- 30 PET cohort, blood glucose and ketone levels were assessed and voxel-wise maps of the cerebral
- metabolic rate of glucose (CMRglc) were computed at each session. For the MRI cohort, brain anterior 31
- 32 cingulate BHB levels were assessed using magnetic resonance spectroscopy.

#### 33 **Results**

- 34 A single dose of KE elevated blood BHB and anterior cingulate BHB levels compared to baseline.
- 35 Moreover, blood glucose levels were lower with KE than baseline, and whole-brain CMRglc decreased
- by 17%. The largest KE-induced CMRglc reductions were in the frontal, occipital, cortex, and anterior 36
- 37 cingulate cortices.

#### 38 Conclusion

39 These findings provide preliminary evidence that KE administration elevates ketone and reduces brain

40 glucose metabolism in humans, consistent with a shift from glucose to ketones as a brain energy source.

41 Average reductions in CMRglc of 17% are similar to global average reductions documented with

- 42 administration of 0.25-0.5 g/kg of alcohol. Documenting the clinical and neurometabolic effects of
- nutritional ketosis will yield fundamental knowledge as to its potential beneficial effects as a treatment 43
- 44 for AUD and its underlying neural mechanisms.
- 45

#### 46 1 Introduction

- 47 Alcohol use disorder (AUD) is a chronic, relapsing condition that is associated with substantially
- 48 elevated risk of neurocognitive impairments, co-occurring medical and psychiatric disorders, and
- 49 mortality. In the United States, approximately 95,000 alcohol-related deaths were reported annually
- 50 between 2011 and 2015, making alcohol the third-leading cause of preventable death (Esser et al.
- 51 2020). However, only 1.6 % of patients with AUD receive FDA-approved medications to treat the
- 52 disorder (Han et al. 2021) and available treatments are not efficacious for all patients (Campbell et al.
- 53 2018).
- 54 Improving brain energetics in individuals with AUD is a novel potential therapeutic intervention
- 55 (Mahajan et al. 2021; Wiers et al. 2021). Acute alcohol intake increases the utilization of acetate, a
- 56 metabolite of alcohol, at the expense of glucose utilization (Volkow et al. 2013; Volkow et al. 2017).
- In individuals with AUD, low brain glucose and high acetate metabolism persist beyond acute 57
- 58 intoxication (Jiang et al. 2013; Tomasi et al. 2019; Volkow et al. 2017; Wang et al. 2013).
- 59 Deprivation of acetate as an energy source during abstinence may contribute to alcohol withdrawal
- 60 signs and symptoms, alcohol craving, and relapse in individuals with AUD (Mahajan et al. 2021).
- 61 Ketone bodies [β-hydroxybutyrate (BHB)], acetoacetate, and acetone) resemble acetate and may
- provide an alternative to it as an energy source in the brain (Courchesne-Loyer et al. 2017). Previous 62
- 63 work in our laboratory has demonstrated the efficacy of a high-fat, low-carbohydrate ketogenic
- 64 dietary intervention in reducing alcohol withdrawal severity and alcohol craving in AUD patients
- 65 undergoing alcohol detoxification (Wiers et al. 2021). These findings are concordant with preclinical
- models showing that a ketogenic diet reduces both the signs of alcohol withdrawal (Bornebusch et al. 66
- 2021; Dencker et al. 2018; Tanabe et al. 2021) and alcohol self-administration (Blanco-Gandía et al. 67
- 68 2021; Wiers et al. 2021).
- 69 Given the restrictive nature of the KD and poor patient adherence to the strict dietary regimen (Ye et
- 70 al. 2015), exogenous BHB ketone supplementation provides an easier alternative to elevate plasma
- 71 ketone bodies (Stubbs et al. 2017). Exogenous ketone supplementation is a well-tolerated
- 72 intervention that may pose various health benefits: ketones improved cognition in preclinical and
- 73 clinical models of Alzheimer's Disease (Kashiwaya et al. 2013; Newport et al. 2015; Pawlosky et al.
- 74 2020); stabilized brain networks, thereby protecting the hypometabolic, aging brain (Mujica-Parodi
- 75 et al. 2020); and decreased appetite in healthy human volunteers (Stubbs et al. 2018). Preclinical
- 76 studies of AUD found that exogenous ketone ester (KE) decreases alcohol withdrawal signs, similar
- 77 to a ketogenic diet (Bornebusch et al. 2021). However, the ability of exogenous KE to cross the blood
- 78 brain barrier and alter brain energetics in AUD has not been demonstrated.
- 79 Here, we piloted the pharmacokinetic effects of a single dose of KE on brain energetics, measured
- 80 with either positron emission tomography (PET) with 18F-Fluoro-deoxyglucose (18F-FDG) or
- 81 proton magnetic resonance spectroscopy (1H-MRS) in individuals with AUD. All participants
- 82 underwent two imaging sessions, once after KE intervention and once without KE (baseline). We
- 83 chose the anterior cingulate cortex (dACC) as the main region of interest for 1H-MRS because
- 84 previous studies have evidenced a role for the dACC in inhibitory control (Gan et al. 2014), alcohol
- 85 craving (Bauer et al. 2013), and decision making (Acheson et al. 2009) and associated aberrations in
- the dACC with subsequent worsening of problems with alcohol (Cheetham et al. 2014; Zakiniaeiz et 86 87 al. 2017). Furthermore, our previous research showed significant effects of a ketogenic diet on brain
- 88
- ketone and glutamate metabolism and functional reactivity to alcohol cues in the dACC (Li et al. 89
- 2022; Wiers et al. 2021). We hypothesized that a single dose of KE would increase BHB levels in the
- 90 brain and decrease the cerebral metabolic rate of glucose (CMRglc). For Original Research

91 Articles, Clinical Trial Articles, and Technology Reports the introduction should be succinct, with

- 92 no subheadings. For **Case Reports** the Introduction should include symptoms at presentation,
- 93 physical exams and lab results.

#### 94 2 Methods

#### 95 2.1 Participants and ketone ester intervention

96 Study participants were recruited for study protocol NCT04616781 or NCT05015881 via online advertisements (BuildClinical, iConnect) and underwent the following screening assessment: Mini 97 98 International Neuropsychiatric Interview (MINI) for a DSM-5 diagnosis of AUD and other 99 neuropsychiatric disorders (1), a 30-day Timeline Follow-back (TLFB) for daily drinking patterns (2), the Alcohol Use Disorders Identification Test (AUDIT) for hazardous drinking behavior (3), and the 100 101 Shipley Institute of Living Scale-2 (Shipley-2) test for crystallized and fluid intelligence (4). Inclusion 102 criteria included: 1) meeting DSM-5 criteria for current AUD; 2) self-report of an average of at least 103 15 standard drinks per week in the last month; 3) self-report of having greater than a 1-yr history of 104 heavy drinking; 4) having had a drink within 1 week of the study visit. Exclusion criteria included: 1) 105 a current DSM-5 diagnosis of a major psychiatric disorder other than AUD; 2) intake of psychoactive 106 medication within 24 hours of study participation; 3) history of seizures; 4) HIV seropositivity; 5) a 107 history of head trauma with loss of consciousness for more than 30 min or associated skull 108 fracture/abnormal MRI; 6) any contraindication for MRI (e.g., presence of ferromagnetic objects or 109 claustrophobia), 7) a current, clinically significant physical disease or abnormality detected by medical 110 history, physical examination, or routine laboratory evaluation that can impact brain function. A 111 medical history and physical examination by a physician and routine laboratory results evaluated by a 112 physician were conducted prior to study inclusion. Five AUD participants completed the MRI study (2 113 females/3 males;  $45.2 \pm 17.0$  years old), and four AUD participants completed the <sup>18</sup>F-FDG procedures 114 (4 males; 31±10 years old) (**Table 1**). Two study participants were enrolled in both studies. The study protocols were approved by the University of Pennsylvania Institutional Review Board and all 115 116 participants provided written informed consent before study participation.

- Both study protocols used a cross-over design, in which a computer-generated randomization scheme
- assigned 50% of subjects to start with KE and 50% without KE on study visit 1, and the reverse on visit 2. On the active day, KE ((R)-3-hydroxybutyl (R)-3-hydroxybutyrate KE solution, TdeltaS Global
- 119 Visit 2. On the active day, KE ((K)-3-hydroxybutyr (K)-3-hydroxybutyr (K)-3-hydrox
- Participants in the MRI study were asked to fast overnight and consumed a low-calorie breakfast approximately 2 hours before the scan. Participants were blinded to the study intervention and, during the baseline visit, received an isocaloric dextrose placebo (baseline) that was taste-matched using a bitterness additive (Symrise, US). The study drinks were prepared by the Penn Investigational Drug Service and provided to the participants 15 minutes prior to the MRI scan or approximately 45 minutes prior to the lu MRS scan
- 126 prior to the <sup>1</sup>H-MRS scan.
- 127 Participants in the PET <sup>18</sup>F-FDG study fasted for at least 6 hours prior to the study, as per standard <sup>18</sup>F-
- 128 FDG study protocols. Participants were aware of the study intervention. KE was diluted with diet soda
- 129 or sparkling water by a trained staff member and administered to participants 1 hr prior to the PET
- 130 scan. No intervention was provided on baseline (no KE) days.

### 131 **2.2 Blood measures of ketones and glucose**

- 132 Blood BHB and glucose levels were obtained from individuals participating in the PET <sup>18</sup>F-FDG study.
- 133 Blood BHB and glucose were measured at arrival, immediately prior to <sup>18</sup>F-FDG injection, and 30 and
- 134 60 min post injection. On KE days, these measures corresponded with the time prior to KE intake, and
- 135 60 (immediately prior to scan), 90, and 120 min following KE intake. Measurements were made using
- 136 a ketone and glucose meter (Abbott, Precision Xtra).

#### 137 **2.3 Brain <sup>1</sup>H-MRS imaging and processing**

138 Participants underwent an MRI on a 3.0T Magnetom Prisma scanner (Siemens Medical Solutions USA

- 139 Inc., Malvern, PA) equipped with a 64-channel head coil. Structural images were acquired using T<sub>1</sub>-
- 140 weighted magnetization prepared rapid-acquisition gradient-echo (MPRAGE) sequences with the
- 141 following parameters: TR 2400 ms; TE 2.24 ms; TI 1060 ms; FOV 256 mm; 208 slices; slice thickness
- 142 0.8 mm; flip angle 9°; effective voxel resolution, 0.8 x 0.8 x 0.8 mm.

Localized proton magnetic resonance spectroscopy (<sup>1</sup>H-MRS) was performed in a region of interest 143 (ROI) located in the dACC (40×30×15mm), for which we previously demonstrated a sensitivity to 144 145 ketones (5, 6). A semi-Laser (sLaser) spectral editing sequence for BHB was acquired, using an adapted 146 sequence previously described (7). The parameters were as follows: TR 2000 ms; TE 72 ms; 256 147 averages; Editing was performed with a gaussian pulse of 18.5 ms, amplitude of 47 Hz, and a bandwith of 80 Hz at FWHM. For edit on, the pulse was centered at 4.14 ppm while for edit-off scans, it was 148 149 centered at 5.26 ppm relative to a water position of 4.70 ppm. First- and second-order shimming was 150 used to maximize the magnetic field B<sub>0</sub> homogeneity in the voxel. Spectral fitting of the <sup>1</sup>H-MRS datasets was carried with in-house written fitting software in IDL (NV5Geospatial, Broomfield, CO, 151 152 USA) (8) with a modified basis set for the specific editing sequence and for ketone bodies (9). The 153 basis set was simulated using GAMMA, part of the VESPA package (soher). The results from the 154 analysis were inspected for nonrandom residuals and baseline fitting. Spectra with signal-to-noise ratio 155 (SNR) < 15 and linewidth > 0.1 ppm were excluded from further analyses. A Cramér–Rao lower bound 156 (CRLBs) of 20% for each individual peak was used as a quality criterion (8). To place the voxel in the 157 dACC ROI during second scan. the program same the ImScribe 158 (https://www.med.upenn.edu/CAMIPM/imscribe.html) was used, which is designed to allow 159 reproducible selection of the same anatomical ROI in Siemens MRI studies within the same subject over multiple MRI scans. ImScribe uses high-resolution T<sub>1</sub>-weighted images and the spectroscopy 160 voxel information from the first scan as target template and  $T_1$ -weighted images of the subsequent scan 161 162 and perform affine coregistration that provides the information of the new spectroscopic voxel placement for the later scans (10, 11). This was completed (~2 minutes) and this ROI was transferred 163 164 to the Siemen's console as a DICOM image and used to prescribe the <sup>1</sup>H-MRS acquisition.

### 165 2.4<sup>18</sup>F-FDG PET scanning and processing

166 On two separate study days participants underwent a 60-min <sup>18</sup>F-FDG PET/CT scan using the PennPET 167 Explorer (12), a 140 cm axial field of view whole-body PET scanner. Venous catheters were placed in 168 the antecubital vein bilaterally for radiotracer injection and blood sampling. Commercially 169 manufactured <sup>18</sup>F-FDG (~10 mCi) was injected intravenously over a period of approximately 1 min. 170 During the PET imaging procedures, the subjects rested quietly under dim illumination and minimal 171 acoustic noise. To ensure that subjects did not fall asleep, they were monitored throughout the 172 procedure and were asked to keep their eyes open.

Dynamic PET images were reconstructed into 4-mm voxels using time-of-flight list-mode orderedsubsets expectation maximization into 39 frames: 12 x 5 s, 6 x 10 s, 3 x 20 s, 2 x 30 s, 6 x 60 s, and 10 175 x 300 s. Images were corrected for interframe motion and analyzed in PMOD v3.7 (PMOD Technologies, Zurich, Switzerland). Whole brain and voxel-wise flux (K) were computed using Patlak 176 graphical modeling (13) and an image-derived aortic arch blood pool SUV<sub>peak</sub> input function with a 177 178 plasma:whole blood ratio of 1:1. Measured <sup>18</sup>F-FDG flux was converted to glucose metabolism using 179 the formula  $MR_{Glc} = K^*PG/LC$ , where PG is the averaged plasma glucose levels from pre-injection, 30-min, and 60-min post-injection samples, and LC is a lumped constant of 0.8 (14). The cerebral 180 181 metabolic rate for glucose consumption (CMRglc) maps in µmol/100 mL/min were aligned to the 182 subject's structural MRI and then normalized to the MNI template with a 2-mm isotropic resolution 183 using the FSL Software Library (version 5.0; http://www.fmrib.ox.ac.uk/fsl)(15).

#### 184 **2.5 Statistical analyses**

All statistical analyses were conducted using SPSS (IBM, Armonk, NY). We performed linear mixed-185 effects analysis to examine the effects of the intervention (KE vs. baseline), time (assessment time 186 points), and time x intervention interaction on blood measures of BHB and glucose. The models also 187 188 controlled for visit order (KE at the first or second visit) and included subject-specific random 189 intercepts. Post hoc pairwise comparisons were performed with Bonferroni correction. Paired t-tests 190 were used to compare cingulate BHB and whole-brain CMRglc between KE and baseline study 191 conditions. Exploratory voxel-wise FDG comparisons between KE vs baseline were performed using 192 a paired t-test in SPM12 (http://www.fil.ion.ucl.ac.uk/spm/) with a cluster-defining threshold of

- uncorrected p<0.0001 and cluster size k>50, and cluster-level threshold of familywise error (FEW)-
- 194 corrected p<0.05.
- 195 **3 Results**

#### 196 **3.1 Blood levels of ketones and glucose**

197 BHB levels were significantly higher following KE than baseline (Intervention:  $F_{1,19,3}=236$ , p<0.001; 198 Intervention x time:  $F_{3,19,3}=36$ , p<0.001) and they changed with time ( $F_{1,19,3}=39$ , p<0.001). Post hoc 199 analysis showed significant differences in BHB levels between baseline and KE at 60-, 90-, and 120-200 min post-KE administration. KE increased blood BHB levels approximately 27 fold from a pre-KE 201 level of 0.15mM  $\pm$  0.12SD to 4.06 mM  $\pm$  0.42SD 120 min following administration (Figure 1A). 202 Blood glucose levels were lower during the KE intervention than baseline (Intervention:  $F_{1,19}=31$ , 203 p<0.001) and changed with time (F<sub>1,19</sub>=12, p<0.001), but no time x intervention interaction effects 204 were observed (F<sub>3,19.0</sub>=1, p=0.4) (**Figure 1B**). *Post hoc* analysis showed lower blood glucose levels 205 between the intervention arms prior to KE administration.

#### 206 2.2 Brain BHB and CMRglc

207 BHB levels in the dACC were significantly higher 45 min after KE intake (mean=0.83 ±0.13 mM)

than baseline visit (mean= $0.28\pm0.11$  mM) (t<sub>4</sub>=13.4, p<0.001), as measured with <sup>1</sup>H-MRS in 5 AUD participants (Figure 2A).

210 Whole-brain CMRglc decreased by 17% with KE (mean CMRglc = 14.4  $\mu$ mol/100g/min ± 1.5SD) vs.

- 211 baseline (mean =  $17.4 \pm 2.3 \mu \text{mol}/100 \text{g/min}$ ) (t<sub>3</sub>=5.7, p=0.01) in 4 AUD participants (**Figure 2B**).
- 212 An exploratory voxel-wise analysis indicated that the largest KE-induced CMRglc reductions were in
- 213 the frontal cortex, including the bilateral inferior frontal gyrus (IFG), occipital cortex, parietal and

temporal lobe, anterior cingulate cortex, bilateral amygdalae, hippocampi and insulae (all pFWE<0.05)

## 215 (Figure 2B. Table 2).

### 216 **4 Discussion**

217 We found that a single dose of the KE (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (TdeltaS Global Inc.)

- rapidly elevated blood ketone levels and shifted brain energetics from glucose to ketones in individuals with AUD. While blood BHB remained low (~0.2 mM) through the baseline visit, it increased to 3.2
- mM within 1 hr of KE administration and to 4.1 mM after 2 hr. Quantification of brain BHB levels and
- 221 glucose utilization with <sup>1</sup>H-MRS and PET, respectively, showed higher dACC BHB levels and lower
- whole-brain glucose metabolism following KE administration compared to baseline in individuals with
- 223 AUD.

224 Glucose is the primary fuel for the brain and is necessary for normal neural functioning, including 225 maintaining a resting potential, generating an action potential, and synthesizing neurotransmitters and 226 neuromodulators (16, 17). Ketone bodies are produced endogenously in the liver during periods in 227 which glucose is not readily available, such as when an individual is adherent to a high-fat, low-228 carbohydrate ketogenic diet. They are carried through the bloodstream and transported into neurons by 229 monocarboxylate transporters, where they are utilized for fuel (18). Exogenous KE supplements 230 provide a faster, less dietary restrictive alternative to a ketogenic diet to achieve nutritional ketosis (19-231 21). As demonstrated in our study, within 1-2 hr of administration KE elevated blood BHB levels 232 similar to those seen following 1-2 wk of adherence to a ketogenic diet (5). Similar blood BHB levels 233 have previously been reported with the same dose of KE (19). Localized <sup>1</sup>H-MRS provides a non-234 invasive method to measure ketone levels in the brains of individuals adhering to a ketogenic diet (9, 235 22). We found rapid and efficient brain uptake of BHB following KE administration and demonstrated 236 significantly higher BHB levels in the dACC during the KE session than the baseline session. 237 Furthermore, KE yielded lower blood glucose levels, which may be due to a small KE-induced increase 238 in insulin levels (19, 23). Moreover, we found an average 17% reduction in CMRglc from baseline to 239 KE, which is comparable to that previously observed following 4 days of a ketogenic diet intervention 240 (24). It is important to note that reductions in CMRglc have been found to be proportionate to plasma BHB levels (25), and not to hypoglycemia per se (24). In contrast, plasma levels of glucose correlate 241 inversely with brain glucose metabolism and hyperglycemia has been associated with significantly 242 243 lower brain glucose metabolism (26). Thus, our findings are in line with previous reports that CMRglc 244 is inversely associated with blood and brain ketone levels (24), and thus that when plasma ketones 245 increase, the human brain meets its metabolic needs by reducing CMRglc in relation to ketone availability and uptake. 246

247 Emerging evidence attributes heavy alcohol consumption and AUD to deficiencies in brain energy 248 metabolism (18, 27). Acetate is a byproduct of alcohol metabolism and produces energy through 249 conversion to acetyl-coenzyme A and metabolism in the tricarboxylic acid (TCA) cycle (28). Alcohol 250 intoxication acutely increases plasma levels of acetate, brain uptake of acetate, and decreases brain 251 glucose utilization (27, 29). Chronic use of alcohol produces metabolic adaptations that exacerbate this 252 shift in brain energetics and increase the brain's reliance on acetate for energy (27, 30). Similarly, gene 253 and protein analysis from rodents and post-mortem human brain tissues show a reduction in glucose 254 metabolism pathways (i.e., glycolysis and gluconeogenesis) and increased expression of 255 monocarboxylated transporters after chronic alcohol use (31, 32). It has been hypothesized that 256 deprivation of acetate as an energy source and inability to abruptly transition to utilizing glucose during 257 abstinence contribute to alcohol withdrawal signs and symptoms and alcohol craving in individuals 258 undergoing detoxication (18, 27). Heavy drinkers also demonstrated higher levels of <sup>13</sup>C-labeled brain 259 acetate than light drinkers (33). Ketone bodies are similar to acetate in that they also are converted to

acetyl-coenzyme A and produce energy in the TCA cycle. Targeting brain energetics with a ketogenic
 dietary intervention was previously shown to increase blood and brain ketone levels and attenuate
 withdrawal signs and symptoms and alcohol craving in individuals with AUD who were undergoing
 alcohol detoxification treatment (5). Here we demonstrated that KE rapidly increases blood and brain
 BHB levels and reduces the need for brain glucose utilization in individuals with AUD, and may thus
 serve as a more palatable alternative to a ketogenic dietary intervention in treating individuals with
 AUD.

267 Our study has several limitations and identifies potential areas for future study. First, although we 268 employed a cross-over design to mitigate potential confounding effects of inter-individual differences, 269 the study sample is small. Second, our sample was limited to individuals with AUD. It has been well 270 demonstrated that individuals with AUD have lower brain glucose metabolism than non-dependent 271 healthy controls (27, 34, 35). Moreover, alcohol-induced increases in acetate metabolism correlate with 272 alcohol drinking history and were greater in heavy drinkers than social drinkers, suggesting that heavy 273 or chronic alcohol exposure facilitates the use of acetate as a brain energy substrate (30). Thus, future 274 studies are needed to compare KE-induced increases in BHB levels and reductions in CMRglc between 275 individuals with AUD and non-dependent volunteers, to ascertain whether KE-induced elevations in 276 ketones and reductions in CMRglc are greater among individuals who are very heavy alcohol 277 consumers. Third, <sup>1</sup>H-MRS cannot differentiate between intracellular and extracellular levels of BHB 278 and is thus limited in assessing BHB utilization in the brain. Fourth, post hoc pairwise analysis showed 279 lower blood glucose in the KE treatment arm compared to the baseline visit prior to KE administration, 280 which may have been confounding. However, all CMRglc analyses were corrected for blood glucose level, and likely did not affect the strong KE-induced reductions in CMRglc. Indeed, previous studies 281 reported an inverse relationship between blood and brain glucose, such that higher brain glucose uptake 282 283 was seen in individuals with lower blood glucose levels (26, 36, 37). Therefore, our findings of 284 decreased brain glucose uptake with KE despite lower blood glucose levels supports the robust effect 285 of KE in altering brain energetics. Last, the implications of KE-induced changes in brain energetics on 286 clinical outcomes in AUD are unknown. To address this gap in the literature, we plan to conduct studies 287 that examine the effects of KE on alcohol withdrawal and alcohol craving in individuals with AUD.

In sum, our findings provide the first evidence that KE administration rapidly shifts brain energetics from glucose to ketone metabolism in individuals with AUD. Understanding the neurometabolic effects of KE may provide a scientific basis for studies examining the feasibility of utilizing KE as a treatment option for AUD or other neuropsychiatric and neurological disorders. Such findings may also help to identify potential neural mechanisms for these clinical effects.

#### 293 **5** Author Contributions

- 294 CEW designed the study. XL, JB, SV, RR, TP, ME, RR, HK, RPRN, JGD collected the data. AY,
- LSP, RKD, RR, RPRN, JVDV, CEW, and ZS analyzed the data and interpreted the results. XL, ZS,
- 296 HK, AY, RPRN, and CEW wrote the manuscript. All authors provided critical revision of the
- 297 manuscript for intellectual content and approved the final version of the manuscript.

#### 298 6 Funding

This work was supported by the Institute for Translational Medicine and Therapeutics' (ITMAT) Transdisciplinary Program in Translational Medicine and Therapeutics (Wiers & Dubroff), a NARSAD Young Investigator Grant (28778, Wiers), and the following National Institutes of Health grants: AA026892 (Wiers), DA051709 (Shi), DA046345 (Kranzler), and and P41 EB029460 (Reddy). Dr. Li was supported by T32DA028874.

#### **304 7 Acknowledgments**

We thank Laurie Downing, Kim Olson, Klaudia Glogowska, Rachel Weyl, Erin Schubert, Matt Furey,
Regan Scheffer, Kayla Spooner, Reagan Wetherill, Nora Volkow, Paco Bravo, Aiden Adams, David
Mankoff, Robert Mach, and the Penn PET Center for their contributions.

#### 308 8 Conflict of Interest

309 The authors declare that the research was conducted in the absence of any commercial or financial 310 relationships that could be construed as a potential conflict of interest.

#### 311 9 Data Availability Statement

The data that support the findings of this study are available from the corresponding author uponreasonable request.

#### 314 10 References

Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured
 diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 Suppl 20:22 33;quiz 4-57.

Sobell LC, Sobell MB. Timeline follow-back: A technique for assessing self-reported alcohol
 consumption. Measuring alcohol consumption: Psychosocial and biochemical methods. Totowa, NJ,
 US: Humana Press/Springer Nature; 1992. p. 41-72.

Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol
 Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of
 Persons with Harmful Alcohol Consumption--II. Addiction. 1993;88(6):791-804.

325 4. Zachary RA, Paulson MJ, Gorsuch RL. Estimating WAIS IQ from the Shipley Institute of
 326 Living Scale using continuously adjusted age norms. J Clin Psychol. 1985;41(6):820-31.

327 5. Wiers CE, Vendruscolo LF, van der Veen J-W, Manza P, Shokri-Kojori E, Kroll DS, et al.
328 Ketogenic diet reduces alcohol withdrawal symptoms in humans and alcohol intake in rodents.
329 Science Advances. 2021;7(15):eabf6780.

Li X, Shi Z, Byanyima J, Morgan PT, van der Veen JW, Zhang R, et al. Brain glutamate and
sleep efficiency associations following a ketogenic diet intervention in individuals with Alcohol Use
Disorder. Drug Alcohol Depend Rep. 2022;5.

333 7. Landheer K, Gajdošík M, Juchem C. A semi-LASER, single-voxel spectroscopic sequence
334 with a minimal echo time of 20.1 ms in the human brain at 3 T. NMR Biomed. 2020;33(9):e4324.

8. van der Veen JW, Marenco S, Berman KF, Shen J. Retrospective correction of frequency drift
in spectral editing: The GABA editing example. NMR Biomed. 2017;30(8).

337 9. Cecil KM, Mulkey SB, Ou X, Glasier CM. Brain ketones detected by proton magnetic
 338 resonance spectroscopy in an infant with Ohtahara syndrome treated with ketogenic diet. Pediatr
 339 Radiol. 2015;45(1):133-7.

Wolf DH, Satterthwaite TD, Loughead J, Pinkham A, Overton E, Elliott MA, et al. Amygdala
abnormalities in first-degree relatives of individuals with schizophrenia unmasked by benzodiazepine
challenge. Psychopharmacology (Berl). 2011;218(3):503-12.

11. Nanga RP, Hariharan H, Reddy R. Fully automated macromolecule suppressed single voxel
glutamate spectroscopy (FAMOUS SVGS). J Transl Med. 2016;14(1):220.

345 Dai B, Daube-Witherspoon ME, McDonald S, Werner ME, Parma MJ, Geagan MJ, et al. 12. Performance evaluation of the PennPET explorer with expanded axial coverage. Phys Med Biol. 346 347 2023;68(9). 348 13. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer 349 constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3(1):1-7. 350 Croteau E, Castellano CA, Fortier M, Bocti C, Fulop T, Paquet N, et al. A cross-sectional 14. 351 comparison of brain glucose and ketone metabolism in cognitively healthy older adults, mild 352 cognitive impairment and early Alzheimer's disease. Exp Gerontol. 2018;107:18-26. Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen-Berg H, et al. 353 15. 354 Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage. 355 2004;23 Suppl 1:S208-19. 356 16. Attwell D, Laughlin SB. An energy budget for signaling in the grey matter of the brain. J 357 Cereb Blood Flow Metab. 2001;21(10):1133-45. 358 Mergenthaler P, Lindauer U, Dienel GA, Meisel A. Sugar for the brain: the role of glucose in 17. 359 physiological and pathological brain function. Trends Neurosci. 2013;36(10):587-97. 360 Mahajan VR, Elvig SK, Vendruscolo LF, Koob GF, Darcey VL, King MT, et al. Nutritional 18. Ketosis as a Potential Treatment for Alcohol Use Disorder. Front Psychiatry. 2021;12:781668. 361 362 Stubbs BJ, Cox PJ, Evans RD, Cyranka M, Clarke K, de Wet H. A Ketone Ester Drink 19. 363 Lowers Human Ghrelin and Appetite. Obesity. 2018;26(2):269-73. 364 20. Stubbs BJ, Cox PJ, Evans RD, Santer P, Miller JJ, Faull OK, et al. On the Metabolism of 365 Exogenous Ketones in Humans. Front Physiol. 2017;8:848. 366 Mujica-Parodi LR, Amgalan A, Sultan SF, Antal B, Sun X, Skiena S, et al. Diet modulates 21. 367 brain network stability, a biomarker for brain aging, in young adults. Proceedings of the National Academy of Sciences of the United States of America. 2020;117(11):6170-7. 368 369 22. Wright JN, Saneto RP, Friedman SD. β-Hydroxybutyrate Detection with Proton MR 370 Spectroscopy in Children with Drug-Resistant Epilepsy on the Ketogenic Diet. AJNR Am J 371 Neuroradiol. 2018;39(7):1336-40. 372 Veech RL, Bradshaw PC, Clarke K, Curtis W, Pawlosky R, King MT. Ketone bodies mimic 23. 373 the life span extending properties of caloric restriction. IUBMB Life. 2017;69(5):305-14. 374 Courchesne-Loyer A, Croteau E, Castellano CA, St-Pierre V, Hennebelle M, Cunnane SC. 24. 375 Inverse relationship between brain glucose and ketone metabolism in adults during short-term 376 moderate dietary ketosis: A dual tracer quantitative positron emission tomography study. J Cereb 377 Blood Flow Metab. 2017;37(7):2485-93. 378 Hasselbalch SG, Madsen PL, Hageman LP, Olsen KS, Justesen N, Holm S, et al. Changes in 25. 379 cerebral blood flow and carbohydrate metabolism during acute hyperketonemia. The American 380 journal of physiology. 1996;270(5 Pt 1):E746-51. Sarikaya I, Albatineh AN, Sarikayaa A. Effect of various blood glucose levels on regional 381 26. 382 FDG uptake in the brain. Asia Ocean J Nucl Med Biol. 2020;8(1):46-53. 383 Volkow ND, Wiers CE, Shokri-Kojori E, Tomasi D, Wang GJ, Baler R. Neurochemical and 27. 384 metabolic effects of acute and chronic alcohol in the human brain: Studies with positron emission 385 tomography. Neuropharmacology. 2017;122:175-88. 386 28. Bose S, Ramesh V, Locasale JW. Acetate Metabolism in Physiology, Cancer, and Beyond. 387 Trends Cell Biol. 2019;29(9):695-703. 388 Volkow ND, Wang GJ, Franceschi D, Fowler JS, Thanos PP, Maynard L, et al. Low doses of 29. 389 alcohol substantially decrease glucose metabolism in the human brain. Neuroimage. 2006;29(1):295-390 301. 391 30. Volkow ND, Kim SW, Wang G-J, Alexoff D, Logan J, Muench L, et al. Acute alcohol 392 intoxication decreases glucose metabolism but increases acetate uptake in the human brain. 393 NeuroImage. 2013;64:277-83.

- 394 Bhat UA, Kumar SA, Chakravarty S, Patel AB, Kumar A. Differential Effects of Chronic 31. 395 Ethanol Use on Mouse Neuronal and Astroglial Metabolic Activity. Neurochemical Research. 396 2023;48(8):2580-94. 397 Enculescu C, Kerr ED, Yeo KYB, Schenk G, Fortes MRS, Schulz BL. Proteomics Reveals 32. 398 Profound Metabolic Changes in the Alcohol Use Disorder Brain. ACS Chem Neurosci. 399 2019;10(5):2364-73. 400 Jiang L, Gulanski BI, De Feyter HM, Weinzimer SA, Pittman B, Guidone E, et al. Increased 33. 401 brain uptake and oxidation of acetate in heavy drinkers. J Clin Invest. 2013;123(4):1605-14. 402 Tomasi DG, Wiers CE, Shokri-Kojori E, Zehra A, Ramirez V, Freeman C, et al. Association 34. 403 Between Reduced Brain Glucose Metabolism and Cortical Thickness in Alcoholics: Evidence of 404 Neurotoxicity. The international journal of neuropsychopharmacology / official scientific journal of 405 the Collegium Internationale Neuropsychopharmacologicum. 2019;22(9):548-59. 406 35. Wiers CE, Cabrera E, Skarda E, Volkow ND, Wang GJ. PET imaging for addiction medicine: 407 From neural mechanisms to clinical considerations. Progress in brain research. 2016;224:175-201. 408 36. Sprinz C, Zanon M, Altmayer S, Watte G, Irion K, Marchiori E, et al. Effects of blood 409 glucose level on 18F fluorodeoxyglucose (18F-FDG) uptake for PET/CT in normal organs: an 410 analysis on 5623 patients. Sci Rep. 2018;8(1):2126. 411 Sarikaya I, Sarikaya A, Sharma P. Assessing the Effect of Various Blood Glucose Levels on 37. 412 (18)F-FDG Activity in the Brain, Liver, and Blood Pool. J Nucl Med Technol. 2019;47(4):313-8.
- 413

#### 414 **11 Figure legends**

415 **Figure 1. Blood ketone and glucose levels with Ketone Ester (KE). (A)** Blood ketone (BHB) levels 416 increased 27x with KE (mean baseline =  $0.15 \text{ mM} \pm 0.12$ , KS= $4.06 \text{ mM} \pm 0.42$ , Intervention x Time: 417 F<sub>3,6</sub>=31.37, p<0.001). (B) There was no Intervention x Time effect for glucose levels, but significant 418 main effects of Intervention (F<sub>1,19</sub>=31, p<0.001) and Time (F<sub>1,19</sub>=12, p<0.001).

419

420 Figure 2. Brain pharmacokinetics of Ketone Ester (KE). (A) Beta-hydroxybutyrate (BHB) levels 421 in the anterior cingulate cortex were significantly higher 45 min after KE intake (mean=0.83±0.13) than at the baseline visit (mean= $0.28\pm0.11$ ) as measured with <sup>1</sup>H-MRS in 5 AUD participants. (B) 422 423 Whole-brain metabolic rate of glucose (CMRglc) decreased significantly with KE (mean CMRglc= 424 14.4 $\pm$ 1.5 µmol/100g/min) vs. baseline (mean=17.4 $\pm$ 2.3 µmol/100g/min) in 4 AUD participants. 425 Average whole-brain CMRglc shows the strongest effects of KE in lowering brain glucose metabolism 426 in the frontal cortex, occipital cortex, temporal cortex, and anterior cingulate (all p < 0.05). \*p < 0.05427 \*\*\**p* < 0.001.

428

#### 429 **12 Tables**

430

**Table 1.** Demographics and clinical characteristics of the participants in the <sup>1</sup>H-MRS and <sup>18</sup>F-FDG PET studies. Data are presented as mean  $\pm$  SD

TDOTET studies. Data are presented as mean ± 5D				
Characteristic	MRI study (n=5)	FDG study (n=4)		
Sex at birth	2 females/ 3 males	4 males		
Age (years)	$45.2 \pm 17.0$	$31 \pm 10$		
Race	3 African American/ 2	2 African American/ 2		
	Caucasian	Caucasian		

BMI (kg/m <sup>2</sup> )	$26.3 \pm 5.3$	$30.6 \pm 2.7$		
Shipley IQ score	$106.6 \pm 7.2$	$106.5 \pm 20.0$		
Drinks/week	$28.3 \pm 10.1$	$27.2 \pm 3.0$		
AUDIT	$17.4 \pm 6.8$	$15.0 \pm 4.8$		
Abbreviation: AUDIT, Alcohol Use Disorders Identification Test; BMI, Body-Mass Index				
		•		

**Table 2**. Brain regions showing a significant main effect of Intervention.

Brain Region	Cluster size (mm <sup>3</sup> )	Z	MNI coordinates		
KE < Baseline					
Frontal cortex, IFG, Precentral gyrus	199	5.32	62, 2, 36		
Frontal cortex, IFG, Precentral gyrus, Insula	8449	5.18	-46, -12, 28		
Precuneus, Parietal lobe	524	4.98	-24, -60, 42		
Occipital cortex, Fusiform gyrus, Temporal lobe	4019	4.93	60, -70, 24		
Anterior Cingulate, dACC, Posterior Cingulate	1300	4.53	-8, 14, 26		
Insula	207	4.22	40, 0, 16		
Brainstem, Pons	798	4.21	10, -16, -34		
Amygdala, Hippocampus	332	4.19	-24, -4, -24		
Superior frontal gyrus	174??	4.18	-14, 22, 58		
Amygdala, Hippocampus	193	3.86	38, 0, -20		
Precentral, Middle frontal gyrus	238	3.81	38, -12, 60		
Precuneus, Parietal lobe	399	3.79	30, -56, 48		
Baseline < KE					
No significant clusters					
Abbreviations: dACC, dorsal Anterior Cingulate Cortex, IFG Inferior Frontal Gyrus, MNI,					
Montreal Neurological Institute					